tbuckley/cabot-search huggingface dataset:
Case Report of Acquired Auto-Immune Hemolytic Anemia with Acute Renal Insufficiency
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P01.060 PriCoTTF: a phase I/II trial of Tumor Treating Fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma
Authors: M Glas, B Scheffler, L Lazaridis, U Herrlinger, D Pierscianek, U Sure, M Pröscholdt, P Hau, J Hense, C Kleinschnitz, A Grosu, M Stuschke, S Kebir
Journal: Neuro-Oncology (2018)

Tumor Treating Fields (TTFields) in combination with adjuvant temozolomide (TMZ) as therapy for newly diagnosed glioblastoma (GBM) patients showed significantly increased progression-free survival (PFS), overall survival (OS) and long-term survival rates in the EF-14 phase III trial. In the trial, patients were randomized after completion of radiochemotherapy, and TTFields therapy was initiated in combination with adjuvant chemotherapy. In preclinical settings, TTFields synergistically enhanced efficacy of radiotherapy in GBM, hypothetically by inhibiting DNA damage repair in irradiated cells. The presented phase I/II trial will evaluate safety and feasibilty of TTFields initiated prior and concomitant to combined radiochemotherapy in newly diagnosed GBM. In arm A of this prospective multi-center trial, seven eligible patients with newly diagnosed GBM will be enrolled initially. Provided that treatment is tolerated well, enrollment will continue for up to 20 patients. Patients will be subjected to TTFields after complete wound-healing following surgery. TTFields treatment will be continued throughout radiochemotherapy and adjuvant chemotherapy for six cycles. In total, patients will receive TTFields therapy for approximately nine months. In arm B, elderly patients with a reduced KPS (50 or 60) will be treated with postsurgical TTFields therapy followed by TTFields therapy concomitant to hypofractionated radiotherapy with 40 Gy for three weeks. In line with arm A, TTFields therapy will continue beyond radiotherapy throughout adjuvant chemotherapy for a total of nine months. In the first stage, six patients will be accrued. Under the provision of an acceptable safety profile, seven additional patients will be accrued for a total of thirteen patients. The primary endpoint of the trial is safety and tolerance based on the frequency of a set of predefined treatment-limiting toxicities (TLTs). Secondary endpoints consist in particular of PFS, OS, radiologic response and frequency of adverse events. First experiences will be presented. The objective of this trial is to demonstrate that the administration of TTFields therapy prior and concomitant to radiotherapy and adjuvant chemotherapy is feasible and safe. Moreover, first data obtained on efficacy may serve as a basis for a potential randomized phase III trial.
AN UNPROVED LIBEL ON THE PROFESSION.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Sentence in Infographic in: Visualizing Health Policy infographic
Journal: JAMA (2013)

Last, the assessment should be aligned with the rest of the curriculum.As Miller noted, "assessment drives learning" 2 and so what medical students learn will ultimately be driven by what comes up in examinations.In summative multiple choice questions in end-of-year examinations, the best answer could perhaps more often be "order no further tests."In objective, structured clinical examinations, the scenarios could be built around simulated patients with anxietyrelated physical symptoms who need reassurance rather than drugs or procedures.In this way, assessment will ensure that restraint is not just celebrated but rewarded in that currency that is most tangible to students-higher marks.
CD200 Is a New Prognostic Factor in Multiple Myeloma.
Authors: Jerome Moreaux, Dirk Hose, Thierry X. Reme, Eric Jourdan, Michael Hundemer, Legouffe Eric, Philippe Moine, Philippe Bourin, Marion Moos, Jill Corre, Thomas Mölher, John DeVos, Jean-Francois Rossi, Hartmut Goldschmidt, Bernard Klein
Journal: Blood (2006)
American Radium Society Resident/Fellow Essay Award—1984
Journal: JNCI Journal of the National Cancer Institute (1983)

Journal Article American Radium Society Resident/Fellow Essay Award—1984 Get access JNCI: Journal of the National Cancer Institute, Volume 71, Issue 1, July 1983, Page 224, https://doi.org/10.1093/jnci/71.1.224-b Published: 01 July 1983
Journal summary
Journal: Annals of the Rheumatic Diseases (1991)

LEADERNon-Hodgkin's lymphoma in rheumatoid arthritis p 275 Non-Hodgkin's lymphoma has been associated now with several diseases of autoimmunity, including rheumatoid arthritis and Sjogren's syndrome.This association is probably due to the disease process itself rather than to the treatment we give for these conditions and may well be due to impaired host defence mechanisms against oncogenic viruses.This is not to say, however, that immunosuppressive treatment is entirely blameless.SCIENTIFIC PAPERS Pannus, rheumatoid arthritis, and damage to joints p 278The behaviour of the cartilage-pannus junction is different in rheumatoid arthritis in metatarsophalangeal joints than in the hip and knee.The changes in the metatarsophalangeal joints are those of an invasive pannus with inflammatory cells, whereas in hips and knees they are more those of a metaplastic reaction of the articular cartilage.Perhaps this explains why erosive changes are more likely to be seen in smaller joints but, contrastingly, joint space narrowing and secondary osteoarthritis in larger ones.
THE RESULTS AND PROSPECTS OF TENEMENT-HOUSE REFORM ABROAD.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adrenalectomy and Hypophysectomy in Disseminated Mammary Carcinoma
Journal: JAMA (1961)

AN IMPORTANTarea in the palliative management of cancer is based on the manipulation of endocrine factors in carcinoma of the breast. The basic effort is the alteration of the hormonal milieu of the host, with the intent of creating a hormonal environment which is hostile to the continued growth of the neoplasm. The maximum effectiveness of such alterations becomes apparent as gross regression of neoplasm. The principal measures directed toward the production of such alterations are: administration of hormones (androgens, estrogens, and corticosteroids); and ablation of endocrine organs (ovaries, adrenals, and pituitary). The relative usefulness of administered estrogens and androgens was studied, through a pooling of results from 60 investigators in as many institutions, by the Subcommittee on Breast and Genital Cancer, Committee on Research of the American Medical Association. The final report of this study was published only recently.<sup>1</sup> The present communication is a preliminary
This Week in JAMA
Journal: JAMA (2002)

A Piece of My Mind"The vanity of life lasts until death, whose arrival is certain but almost always surprising.We all look for signs and hints, of change, of decline, intimations of the end."From "Vanity." SEE PAGE 677 Medical News & PerspectivesAt the XIV International AIDS Conference in Barcelona, delegates were confronted with sobering news about the growing epidemic, some good and bad news from biomedical researchers, and hopeful signs of a growing global commitment to help poor nations cope with HIV/AIDS. SEE PAGE 683 Tobacco, Pharmaceutical Company TiesThree case studies illustrate how financial ties between tobacco and pharmaceutical companies have created conflicts of interest that influence the development and marketing of nicotine replacement therapies.
Local Committee on Arrangements
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Industrial Health.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sixty-Seventh Annual Meeting of the American Association for Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Sixty-Seventh Annual Meeting of the American Association for Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 56, Issue 1, January 1976, Page 201, https://doi.org/10.1093/jnci/56.1.201-c Published: 01 January 1976
Treatment of impaired physicians
Authors: R. C. Larsen
Journal: JAMA (1983)

<h3>To the Editor.—</h3> The power of inappropriate mass hysteria to mold public policy is illustrated by the Vietnam Veterans Agent Orange Relief Act, S-374, currently before the first session of the 98th Congress. The bill presumes causation when a disease that could be caused by exposure to phenoxyherbicides meets certain conditions, even though there is no record of evidence of the disease during the period of service. The bill provides that "The Administrator" shall determine the diseases according to credible medical opinion and shall determine what constitutes exposure. The offering of such legislation reflects the influence of a large constituency of veterans whose concerns have been inflamed by the mass media representation of dioxin toxicity. National television has described dioxin toxicity as so great that scientists from around the world flocked to study the accidental spill of dioxin in Seveso, Italy, in 1976. There was no mention that chloracne was
Spiral nerve bands of Fontana.
Journal: BMJ (1972)

for its use in women, for in them the external apparatus, as well as lacking the risks of a major surgical procedure, does not seem to carry any lower degree of success.The present state of the electrical control of incontinence is uncertain, to say the least.A recent statement'7 that we should abandon continuous stimulation aimed at control rather than cure may present an extreme view.But there is much to be said for undertaking this form of treatment, particularly by the implant method, in specialist units.The techniques are not yet sufficiently understood nor in general sufficiently successful to be used outside such units.
American Journal of Mental Deficiency, Albany, NY
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Escherichia coli O157:H7, an emerging gastrointestinal pathogen. Results of a one-year, prospective, population-based study
Authors: K L MacDonald, M J O'Leary, M L Cohen, P Norris, J G Wells, E Noll, J M Kobayashi, P A Blake
Journal: JAMA (1988)

To examine the incidence of Escherichia coli O157:H7 enteric infections in the United States and to evaluate the vehicles of transmission for sporadic cases, we conducted a one-year, population-based study at a large health maintenance organization (HMO) in the Puget Sound area of Washington State. All stool specimens submitted for culture to the HMO laboratory were screened for E coli O157:H7; the organism was identified in 25 (0.4%) of 6485 stool specimens. All patients with E coli O157:H7 identified had diarrhea; 24 patients (96%) had bloody diarrhea. Exposure histories demonstrated that rare ground beef was consumed more often by patients (21%) than by age-matched control subjects (4%) in the week before onset of illness. Raw milk also was consumed by two patients but by none of the control subjects. Incidence rates for laboratory-confirmed enteric infections in the HMO population were as follows: Campylobacter, 50/100,000 person-years; Salmonella, 21/100,000 person-years; E coli O157:H7, 8/100,000 person-years; and Shigella, 7/100,000 person-years. The organism is a more common pathogen in the United States than is generally recognized, and the diagnosis should be considered for patients with suspected enteric infection.
SAT-258-Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients
Authors: Federico Ravaioli, Elton Dajti, Patrizia Simoni, Alberto Porro, Giovanni Marasco, Vanessa Alemanni, Mariarosa Tamé, Marco Montagnani, Stefano Brillanti, Antonio Colecchia, Davide Festi, Giuseppe Mazzella, Francesco Azzaroli
Journal: Journal of Hepatology (2019)
Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Authors: Darren Richard Feldman, James Hu, Tanya B. Dorff, Sujata Patil, Lindsay Joy Van Alstine, Lamia Momen, Maryann Carousso, Amanda Hughes, Jolie Snively-Solomon, Charlean Ketchens, Joel Sheinfeld, Manjit S. Bains, Dean F. Bajorin, George J. Bosl, Robert John Motzer, David I. Quinn
Journal: Journal of Clinical Oncology (2013)

4501 Background: Durable progression-free survival (PFS) rates for pts with intermediate- and poor-risk GCT approximate only 75% and 50%, respectively with standard BEP. This multicenter phase II study investigated first-line TIP in this population. Methods: Pts age ≥18 with untreated, IGCCCG intermediate- (LDH modified to ≥3x upper limit of normal) or poor-risk GCT were eligible. Pts received 4 cycles of TIP every 21 days, consisting of paclitaxel 120mg/m 2 days 1-2; ifosfamide 1200mg/m 2 days 1-5; and cisplatin 20mg/m 2 days 1-5, followed by G-CSF and levofloxacin for neutropenic fever prophylaxis. The primary endpoint was the complete response (CR) rate; secondary endpoints included PFS and toxicity. A Simon’s 2-stage design required a CR in ≥11/18 pts to proceed to stage 2, where with ≥27/41 CRs overall, the regimen would be considered active and worthy of further study. Results: Of 44 men (median age 27) enrolled; 38 had nonseminoma and 6 seminoma; 29 were poor-risk and 15 intermediate-risk. Primary site was testis in 30, mediastinum in 11, and retroperitoneum in 3. 42 pts had elevated markers and 14, 6, and 1 had liver, bone, and brain metastasis, respectively. The trial met its primary endpoint; of 41 evaluable pts, 28 achieved a CR (see Table) and 6 pts (5 with seminoma) achieved a partial response with negative markers (PR-). Two pts relapsed. With a median follow-up of 2.2 years, estimated 3-year PFS was 79% and 3-year overall survival (OS) 98% (see Table). There were no treatment-related deaths. Grade 3/4 toxicities were primarily hematologic and 6 (14%) pts developed neutropenic fever. Conclusions: TIP demonstrates promising efficacy and is well-tolerated in intermediate- and poor-risk GCT pts. A randomized trial of TIP vs. BEP has been initiated to compare efficacy. Clinical trial information: NCT00470366. [Table: see text]
Error in Results and Figures 1, 2, and 3
Authors: Steven Nissen, Sreekumar Pillai
Journal: JAMA Cardiology (2018)

Neal A. Chatterjee, MD, MSc; M. Vinayaga Moorthy, PhD; Julie Pester, BA; Andi Schaecter, BA; Gopi K. Panicker, BHMS, PGDCR; Dhiraj Narula, MD; Daniel C. Lee, MD, MS; Jeffrey J. Goldberger, MD, MBA; Alan Kadish, MD; Nancy R. Cook, ScD; Christine M. Albert, MD, MPH; for the PRE-DETERMINE Study Group
Liver Alone May Not Support Blood Glucose Level
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Privacy and security of personal information in a new health care system
Authors: L. O. Gostin
Journal: JAMA (1993)

A COMPLEX health care information infrastructure will exist under a reformed health care system as proposed in the American Health Security Act of 1993. The success of the new system will depend in part on the accuracy, correctness, and trustworthiness of the information and the privacy rights of individuals to control the disclosure of personal information. All participants in the new system (consumers and patients, health plans, health alliances, and a national health board) will need access to high-quality information for informed decision making. At the same time, everyone must have confidence that information of a private nature is adequately protected. American society places a high value on individual rights, autonomous decision making, and the protection of the private sphere from governmental or other intrusion. Concerns about privacy transcend the health care setting.<sup>1-3</sup>Americans believe that their privacy rights are not adequately protected. In a 1993 Harris-Equifax poll<sup>4</sup>